Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation by Calvo, Pier Luigi et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
Calvo, Pier Luigi; Serpe, Loredana; Brunati, Andrea; Nonnato, Antonello;
Bongioanni, Daniela; Olio, Dominic Dell'; Pinon, Michele; Ferretti, Carlo;
Tandoi, Francesco; Carbonaro, Giulia; Salizzoni, Mauro; Amoroso, Antonio;
Romagnoli, Renato; Canaparo, Roberto. Donor CYP3A5 genotype influences
tacrolimus disposition on the first day after paediatric liver transplantation.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 83 (6) pp:
1252-1262.
DOI: 10.1111/bcp.13219
The publisher's version is available at:
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13219/fullpdf
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/1636408
1	
	
Donor CYP3A5 genotype influences tacrolimus disposition on the first 
day after paediatric liver transplantation 
Pier Luigi Calvo1, Loredana Serpe2*, Andrea Brunati3, Antonello Nonnato4, Daniela Bongioanni5, 
Dominic Dell Olio5, Michele Pinon1, Carlo Ferretti2, Francesco Tandoi3, Giulia Carbonaro3, Mauro 
Salizzoni3, Antonio Amoroso5, Renato Romagnoli3, Roberto Canaparo2 
 
1Department of Pediatrics and Public Health Sciences, Division of Pediatric Gastroenterology, 
A.O.U. Città della Salute e della Scienza of Torino, University of Torino, Torino, Italy 
2Department of Drug Science and Technology, University of Torino, Torino, Italy 
3Department of Surgical Sciences, Liver Transplantation Center, A.O.U. Città della Salute e della 
Scienza of Torino, University of Torino, Torino, Italy 
4Clinical Biochemistry Unit, A.O.U. Città della Salute e della Scienza of Torino, Torino, Italy 
5Department of Medical Sciences, Regional Transplantation Center, A.O.U. Città della Salute e 
della Scienza of Torino, University of Torino, Torino, Italy 
 
Correspondence author: 
*Loredana Serpe MD, PhD 
Department of Drug Science and Technology 
University of Torino, Italy 
Via P. Giuria 9, 10125 Torino, Italy 
Tel.: +39 011 670 6235 Fax: +39 011 670 7788 
E-mail: loredana.serpe@unito.it 
 
Running head 
Donor CYP3A5 genotype in paediatric liver transplantation 
2	
	
Keywords: 
Tacrolimus, CYP3A Genotyping, Therapeutic Drug Monitoring, Cytochrome P450 3A, 
Immunosuppression, Children, Liver Transplantation  
 
Word count: 3765 
 
Numbers of tables: 2 
 
Number of figures: 4 
 
Grants and financial support: 
This work was funded by grants from University of Torino “Ricerca Locale ex 60% 2013” and 
Fondazione CRT, Torino, Italy 
 
Conflicts of interest: All authors declare no support from any organization for the submitted work, 
no financial relationships with any organizations that might have an interest in the submitted work 
and no other relationships or activities that could appear to have influenced the submitted work. 
 
Acknowledgments 
The authors wish to thank Prof. Piero Cervella and Prof Sergio Castellano from the Department of 
Life Sciences and Systems Biology, University of Torino, Italy for their kind help with the Hardy-
Weinberg equilibrium test and statistical analysis, and Ms. Barbara Wade for her linguistic advice. 
 
 
 
 
3	
	
What is already known about this subject 
• Tacrolimus is a drug widely used in paediatric solid organ transplantation.  
• Therapeutic drug monitoring (TDM) was introduced to reach the target blood concentration 
as early as possible after transplantation, to avoid over- or under-dosing however, on the 
first day after transplantation, the tacrolimus dose is calculated according to body weight or 
body surface and it is not TDM guided. 
• Liver donor CYP3A genotypes influence tacrolimus blood concentration in adult recipients. 
What this study adds 
• On the first day after paediatric liver transplantation, the donor CYP3A5 genotype influences 
tacrolimus blood concentration more than the donor CYP3A4 genotype  
• Physiological factors, mainly recipient age, may also play a role in tacrolimus disposition on 
the first day after paediatric liver transplantation. 
• There is a quick recovery of CYP3A enzyme activity in the liver graft after transplantation 
• The tacrolimus therapeutic range may be reached more quickly if the initial, not yet TDM 
guided, doses are doubled in paediatric patients under 6 years of age who receive a graft 
from a male extensive metabolizer. 
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Tables of Links 
TARGETS 
Enzymes 
CYP3A4 
CYP3A5 
 
LIGANDS 
Tacrolimus 
These Tables list key protein targets and ligands in this article that are hyperlinked to corresponding 
entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY, and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2015/16 [1]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5	
	
Summary 
AIM 
The aim of our study was to investigate the influence of the CYP3A4/5 genotype in paediatric liver 
transplant recipients and donors and what contribution age and gender make to tacrolimus 
disposition on the first day after transplantation. 
METHODS 
The contribution of the CYP3A4/5 genotype in paediatric liver transplant recipients and donors to 
the tacrolimus blood trough concentrations (C0) and tacrolimus concentration/weight-adjusted dose 
ratio on day one was evaluated in 67 liver transplanted children: 33 boys and 34 girls, mean age 4.5 
years.  
RESULTS 
Donor CYP3A5 genotype appears to be significantly associated with tacrolimus disposition on the 
first day after liver transplantation (P < 0.0002). Other physiological factors, such as the recipient 
age and donor gender may also play a role and lead to significant differences in tacrolimus C0 and 
tacrolimus concentration/weight-adjusted dose ratio on day one. However, according to the linear 
general model, only recipient age appears independently associated with tacrolimus disposition on 
the first day after liver transplantation (P < 0.03). Indeed, there was a faster tacrolimus metabolism 
in children under 6 years of age (P  < 0.02). 
CONCLUSIONS 
Donor CYP3A5 genotype, recipient age and, to a lesser extent, donor gender appear to be associated 
with tacrolimus disposition on day one after transplant. This suggests that increasing the starting 
tacrolimus doses in paediatric patients under 6 years of age, who receive a graft from a male 
extensive metabolizer, may enhance the possibility of their tacrolimus levels reaching the 
therapeutic range sooner. 
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Introduction 
Tacrolimus is a calcineurin inhibiting immunosuppressant drug widely used in solid organ 
transplantation [2] which is effective in the management both of adult and paediatric transplant 
patients [3]. However, this drug has a narrow therapeutic index, exposing patients to a risk of acute 
graft rejection or toxicity if its blood concentrations are respectively too low or too high. Moreover, 
tacrolimus concentrations and pharmacokinetics vary considerably on the first day after 
transplantation, thus complicating dose calculations. Therefore, therapeutic drug monitoring (TDM) 
was introduced in order to reduce variability and avoid over- or under-dosing. TDM may be carried 
out by measuring the tacrolimus trough concentration in peripheral blood 12 hours after a dose (C0) 
or by the area under the concentration-time curve (AUC), with the primary goal of maintaining C0 
and AUC within a predefined therapeutic range [4]. Thus TDM is crucial for optimizing treatment 
efficacy, reducing rejection episodes and preventing adverse effects in daily practice. However, 
despite the undoubted contribution by TDM in improving long-term patient and graft survival, it 
has been demonstrated that reaching quickly the immunosuppressant target concentrations is crucial 
[5]. Recent literature has reported that patients should reach target blood concentrations as early as 
possible in the first week after transplantation to minimize early rejection risk [6]. This is especially 
important in paediatric recipients, where certain factors, such as growth, age-related changes, as 
well as time from transplantation, co-medications and hepatic and renal function, may influence the 
response to immunosuppressants. Therefore, choosing the correct first oral dose of tacrolimus, 
when it is not yet TDM guided, may well reduce the time needed to reach the drug therapeutic 
window and prove beneficial particularly in paediatric liver transplant patients. 
To meet this goal, numerous authors have suggested that some genetic factors, such as the 
polymorphisms in genes coding for biotransformation enzymes (cytochrome P450 (CYP) 
isoenzymes 3A4 and 3A5) should be taken into account to guide the initial tacrolimus dosing [7]. 
Indeed, it has been consistently demonstrated that CYP3A5 expressers (CYP3A5*1/*1 and *1/*3 
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carriers) have lower C0 levels and higher oral clearance (CL/F), thus requiring higher tacrolimus 
doses to reach the same C0 at steady-state than CYP3A5 non-expressers (CYP3A5*3/*3 carriers). 
These findings support the case for a strategy of pharmacogenetic-based dosing of tacrolimus [8]. A 
new SNP in intron 6 (15289C>T; CYP3A4*22) has recently been described, which demonstrates 
decreased CYP3A4 mRNA hepatic expression and a lower microsomal CYP3A4 enzymatic activity 
in the T-variant allele [9]. Although the effect of this newly described CYP3A4 polymorphism on 
tacrolimus dosing requirements and trough blood concentrations has been extensively investigated 
in adults, data in children are scanty [10, 11]. 
A retrospective study was carried out to evaluate whether the CYP3A4/5 combined genotype 
approach in paediatric liver recipients and donors could achieve target blood tacrolimus 
concentrations more quickly. The contribution of other factors, such as age and gender, on 
tacrolimus disposition on the first day after transplantation was also investigated. 
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Patients and methods 
A total of 67 paediatric patients (aged <18 years at transplant) managed on oral tacrolimus after a 
liver transplant performed at A.O.U. Città della Salute e della Scienza, Torino, Italy, were enrolled 
into the study. DNA samples from the recipients and their donors were provided by the Regional 
Transplantation Center (CRT Piemonte e Valle d'Aosta, Italy) (Table 1). 
Approval of the local ethics committee (protocol identification number 15386/28.3) was obtained, 
as was a written informed consent from the patients’ parents or guardians. A population study for 
CYP3A4*22 single nucleotide polymorphism (SNP) was also performed on peripheral blood 
samples collected from 262 unrelated healthy adult volunteers of Italian-Caucasian descent, 
recruited from blood donors at the Centre’s blood bank, A.O.U. Città della Salute e della Scienza, 
Torino, Italy. This population study also was approved by the local ethics committee (protocol 
identification number 8802/A5.4) and written informed consent was obtained from all participants. 
Induction therapy with an interleukin-2 receptor antagonist (basiliximab) was administered to 52/67 
patients and the first tacrolimus dose was given perioperatively in all (Table 1). Tacrolimus was 
then administered orally or via naso-gastric tube on the first day in all transplanted patients, to reach 
a total daily dose of 0.15 mg/Kg/day as per protocol. TDM was used to adjust the subsequent 
tacrolimus doses aiming at reaching a target C0 of 10-12 ng/ml. Steroids were added in 41/67 
patients (Table 1). 
 
Tacrolimus concentration measurement 
Tacrolimus blood trough concentrations were quantified according to the Waters MassTrak 
Immunosuppressants XE Kit protocol, taking into account the Lake Louise Consensus document for 
therapeutic drug monitoring. Instrumental analysis was performed on Waters AcquityTM Ultra 
Performance Liquid Chromatography (UPLC) coupled to a Waters Acquity Tandem Quadrupole 
Mass Spectrometry Detector (TQD) [12]. 
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Criteria adopted to satisfy the guidelines on tacrolimus therapeutic drug monitoring in whole-blood 
samples take into account the measured quality control values within 10% of the values stated in the 
certificate of analysis, performed at least once per day at the initial run batch. 
Accuracy of tacrolimus quantification was checked by participating in an external proficiency-
testing scheme, set up by Bionalytics, UK. 
The tacrolimus trough concentration for the effect of dose adjustments were normalized to obtain 
the tacrolimus trough concentration/weight-adjusted dose ratio, as the tacrolimus trough 
concentration, in itself, does not well define the variability in doses and blood levels of tacrolimus 
between different transplant patients [7, 13, 14]. 
 
Genotyping 
Donor and recipient DNA samples were genotyped for CYP3A4*22 and CYP3A5*3 using the allelic 
discrimination reaction performed with TaqMan (Thermo Fisher Scientific). The CYP3A4*22 assay 
was validated by sequencing homozygous wild-type (*1/*1), heterozygous (*1/*22), and 
homozygous mutant (*22/*22) samples. When whole body metabolism was considered, the patients 
were classified as rapid metabolizers (RM) if the donor/recipient pair carried all, or at least five, 
CYP3A4/5*1; as extensive CYP3A4/5 metabolizers (EM), if they carried four CYP3A4/5*1 alleles; 
as intermediate CYP3A4/5 metabolizers (IM), if they carried none, or up to three CYP3A4/5*1 
alleles in their recipient and donor DNA (Table 2). 
When only recipient or donor metabolism were considered, the patients were classified as RM if 
they carried all or three CYP3A4/5*1 alleles, as EM if they carried two CYP3A4/5*1 alleles and as 
IM if they carried none, or one CYP3A4/5*1 allele. 
 
Statistical analysis 
Data are presented as mean and standard deviation (SD) or as median and interquartile range (IQR). 
Differences were compared using either the Kruskal-Wallis or the Mann-Whitney tests, as 
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appropriate, and a P value of less than 0.05 was taken as statistically significant. A general linear 
model was performed to test the overall contribution of CYP3A5 genotype, donor gender and 
recipient age to tacrolimus levels. All data analyses were carried out using SPSS 23.0 software 
(SPSS, Chicago, IL). 
The Hardy-Weinberg equilibrium was calculated with the method described by Rodriguez et al. 
[15]. 
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Results 
Patient characteristics 
Table 1 reports on the 67 paediatric liver transplant patients who were eligible for the study, with 
the demographic details of recipients and donors  
 
Tacrolimus disposition 
Data for tacrolimus concentration (ng/ml) and concentration/weight-adjusted dose ratio 
(ng/ml/dose) on the first day after liver transplantation were available for all patients. The median 
tacrolimus blood trough concentration was 7.8, IQR 9.1 ng/ml and the median 
concentration/weight-adjusted dose ratio was 95, IQR 111 ng/ml/dose (Figures 1A and B). A total 
of 67.2% of all analyzed concentrations fell below the target range of 10-12 ng/ml, whilst 25.4% 
were higher than the upper desired limit (Figure 1A). 
 
Influence of other drugs, graft-recipient weight ratio, gender and age on tacrolimus 
disposition on the first day after liver transplantation 
No influences of glucocorticoids, antifungal drugs or graft-recipient weight ratio (GRWR) on 
tacrolimus trough concentrations or on the concentration/weight-adjusted dose ratios were observed 
in our paediatric population on the first post-transplant day, whereas the donor gender and the age 
of the recipient did seem to play a major role in tacrolimus disposition. On the first day after 
transplant, recipients of a male donor graft had a median C0 of 5.6, IQR 7 ng/ml, whilst recipients 
of a female organ had a median C0 of 9.7, IQR 10 ng/ml (P < 0.02) and median 
concentration/weight-adjusted dose ratios of 87, IQR 125 vs 147, IQR 113 ng/ml/dose (P < 0.04). 
Age related differences in our patients, stratified for an age at transplant under or above 6 years, 
were observed only in the recipients and exclusively for the tacrolimus concentration/weight-
adjusted dose ratios (86, IQR 123 ng/ml/dose under 6 years of age vs 139, IQR 100 ng/ml/dose 
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above 6 years of age (P < 0.02) (Figure 2). The discrepancy observed in the statistical significance 
when comparing the groups only according to tacrolimus concentration/weight-adjusted dose ratio 
might well be found in how the dose-normalization better defines the wide intervariability in the 
tacrolimus trough concentration among paediatric transplant patients compared to tacrolimus trough 
concentration without dose normalization. 
 
Frequency of CYP3A4 and CYP3A5 variants in paediatric liver transplant recipients and 
donors 
DNA samples for CYP3A4 and CYP3A5 genotyping were available for all 67 patients and their 
donors. 
Taking into consideration the recipients’ CYP3A4 genotype, fifty-nine (88%) carried the 
CYP3A4*1/*1 genotype, six (9%) carried the CYP3A4*1/*22 genotype and two (3%) carried the 
CYP3A4*22/*22 genotype. 
The CYP3A4 genotyping of donors showed that fifty-five (82%) carried the CYP3A4*1/*1 
genotype, eleven (16%) carried the CYP3A4*1/*22 genotype and one (1.5%) carried the 
CYP3A4*22/*22 genotype. 
Taking into consideration the recipients’ CYP3A5 genotype, one (1.5%) carried the CYP3A5*1/*1 
genotype, eight (12%) the CYP3A4*1/*3 genotype and fifty-eight (87%) of the patients carried the 
CYP3A5*3/*3 genotype. The CYP3A5 donor genotyping showed that one (1.5%) carried the 
CYP3A5*1/*1 genotype, twenty-eight (33%) carried the CYP3A5*1/*3 genotype and forty-four 
(66%) of the patients carried the CYP3A5*3/*3 genotype. According to the frequency of CYP3A4 
and CYP3A5 variants in our paediatric liver transplant patients, an higher frequency of CYP3A5*1 
allele in donors was observed, suggesting that some liver donors might come from ethnic groups 
where the CYP3A5*1 allele frequency is higher than in Caucasian subjects [16]. We cannot rule out 
this possibility since individuals from Asia or Africa are nowadays a significant demographic 
presence in Italy. 
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Both recipients' and donors' CYP3A4 and CYP3A5 genotypes were tested by the Hardy-Weinberg 
equilibrium test, and only the recipients’ CYP3A4 genotype showed equilibrium deviations (chi-
square = 8.28, P = 0.05). Sequencing confirmed the CYP3A4 genotype in the paediatric liver 
transplant recipients. 
In order to determine whether the deviation from equilibrium observed in the recipient paediatric 
population may have been due to genotyping errors, or to biological factors,  CYP3A4*22 SNP was 
confirmed by sequencing the PCR products and genotyping for CYP3A4*22 SNP 262 was carried 
out on a healthy unrelated adult population of identical extraction. No deviation from the Hardy-
Weinberg equilibrium (chi-square = 0.83, P = 0.05) was observed in the control population. 
Therefore, the deviation from the Hardy-Weinberg equilibrium observed in the CYP3A4 genotyping 
of the paediatric recipient population may well be due to the small number of patients.  
 
Influence of CYP3A4/5 combined-genotype approach on tacrolimus disposition on the first 
day after liver transplantation 
Whole body metabolism on the first day after liver transplantation was investigated in the 
donor/recipient pairs through a CYP3A4/5 combined-genotype approach. Statistically different 
tacrolimus trough concentrations (C0) were detected between rapid, extensive and intermediate 
metabolizers (4.1, IQR 6.3 RM vs 9.2, IQR 8.9 EM ng/ml P < 0.005; 4.1, IQR 6.3 RM vs 8.5, IQR 
8.5 IM ng/ml; P < 0.02) (Figure 3), whilst there were no statistically significant differences in the 
tacrolimus concentration/weight-adjusted dose ratios. The difference in behavior between 
tacrolimus C0 and concentration/weight-adjusted dose ratio prompted the investigation of the 
influence the CYP3A4/5 combined-genotype approach on tacrolimus disposition had in the 
recipients (extrahepatic metabolism) and in donors (hepatic metabolism) on the first day after 
transplantation. In our opinion, the lack of statistical significance, when we compared the whole 
body metabolism groups according to the tacrolimus trough concentration/weight-adjusted dose, 
was possibly due to the physiological variables included in our statistical analysis.  
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Indeed, no statistical differences in extrahepatic metabolism were observed between rapid, 
extensive or intermediate metabolizers, stratified by the CYP3A4/5 combined-genotype approach. 
Instead, statistical differences were observed in hepatic metabolism between rapid, extensive and 
intermediate metabolizers both for the tacrolimus C0 (3.0, IQR 6.6 RM vs 8.5, IQR 9.0 EM ng/ml P 
< 0.003; 3.0, IQR 6.6 RM vs 9.5, IQR 7.1 IM ng/ml P < 0.004) and for the concentration/weight-
adjusted dose (62, IQR 68 RM vs 122, IQR 103 EM ng/ml P < 0.003; 62, IQR 68 RM vs 184, IQR 
148 PM ng/ml/dose P < 0.02). 
 
Effect of CYP3A4 and CYP3A5 liver genotypes on tacrolimus disposition on the first day after 
liver transplantation. 
Since the recipient CYP3A4/5 combined-genotypes did not seem to play an important role in 
tacrolimus disposition in our paediatric population, we turned our attention to the donors’ CYP3A4 
and CYP3A5 genotypes, investigating the contribution of these metabolic enzymes to tacrolimus 
disposition on the first day after liver transplantation. 
Patients carrying both liver CYP3A4*22/*22 and *1/*22 were pooled, and a comparison was made 
between CYP3A4*1/*1 and CYP3A4*1/*22-*22/*22. No statistically significant differences were 
observed between the two groups, either in tacrolimus C0 or in concentration/weight-adjusted dose 
ratios. When the same statistical analysis was performed on liver CYP3A5*1/*1-*1/*3 and 
CYP3A5*3/*3 patients, statistically significant differences were observed between the two groups in 
tacrolimus C0 (3.0, IQR 5.3 (*1/*1-*1/*3) vs 9.1, IQR 8.6 (*3/*3) ng/ml; P < 0.0002) and 
concentration/weight-adjusted dose ratios (62, IQR 65 (*1/*1-*1/*3) vs 147, IQR 123 (*3/*3) 
ng/ml/dose; P < 0.0002) (Figure 4A and B). 
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Interplay of recipient age, donor gender and donor CYP3A5 genotype on tacrolimus 
disposition on the first day after liver transplantation.  
Since in our paediatric population recipient age, donor gender and donor CYP3A5 genotype seem to 
play a role in tacrolimus disposition on the first day after liver transplantation, we performed a 
statistical analysis to show the overall contribution of the donor CYP3A5 genotype, donor gender 
and recipient age on tacrolimus disposition. 
According to the linear general model, only the donor CYP3A5 genotype and the recipient age were 
independently associated with tacrolimus disposition, P < 0.03 and P < 0.02, respectively, whilst the 
donor gender seemed to play a minor role. 
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Discussion 
Our data show that, on the first day after transplantation, less than 8% of our paediatric liver 
transplant patients had a tacrolimus trough blood concentration within the therapeutic range (10-12 
ng/ml). In keeping with the assumption that an appropriate early systemic tacrolimus exposure is 
clinically relevant for a smooth post-transplant course, it could be argued that a majority of our 
paediatric population may have been exposed to the risk of adverse drug-related events, ranging 
from graft rejection to drug toxicity [5] . 
Tacrolimus dosage was TDM monitored in all patients in order to reduce the time lag required to 
reach a stable tacrolimus trough blood concentration within the therapeutic range. However,  
relying on TDM guided dose adjustments means that the desired target concentrations are reached 
only days or even weeks after transplantation. To overcome this drawback, many authors have 
suggested that factors such as recipient age, baseline histological score of the graft, co-medication, 
creatinine clearance, CYP3A5 genetic polymorphism and CYP3A4 expression rates of donors [14, 
17-19] should be taken into account and guide the daily tacrolimus administration. This is 
particularly relevant on the first day after transplantation, when the tacrolimus dose is calculated 
according to body weight or body surface area and TDM has not yet been started.  
A novel SNP located in intron 6 of the CYP3A4 gene, CYP3A4*22, has been associated with 
reduced CYP3A4 mRNA expression in the liver [9] and its contribution to tacrolimus metabolism 
has been confirmed in kidney, heart and liver transplantation [10, 11, 20]. Our study investigated 
the role that CYP3A4/5 combined genotypes play on tacrolimus trough blood concentration and 
tacrolimus concentration/weight-adjusted dose ratio on the first day after liver transplantation in 
children. Concomitant drugs, graft-recipient weight ratio, gender and age were also taken into 
account. Graft-recipient weight ratio and co-medications did not affect tacrolimus disposition on the 
first day after liver transplantation in our paediatric liver transplant recipients. Our findings on the 
effect of co-medications differ from those of other studies, where co-administered drugs, in 
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particular fluconazole, were reported to be the most important covariate influencing tacrolimus 
CL/F [20]. However, these studies investigated tacrolimus disposition in transplant patients over a 
longer time period, when drug induction and inhibition on the CYP450 system are more consistent. 
On the first day after liver transplantation the co-medications effect on tacrolimus disposition may 
not be so relevant due to the time these drugs need to exert their effect on the CYP450 enzymes.  
Conversely, a gender effect was observed from the first post-transplant day, as male donor grafts 
engendered lower tacrolimus trough concentrations and lower tacrolimus concentration/weight-
adjusted dose ratios than female donors, with median values below the therapeutic range. These 
data are in contrast with the results reported by others [21, 22], who observed significantly lower 
areas under the curve values in women than in men in adult kidney transplanted patients. Thangavel 
et al. also reported a female predominant expression of human CYP3A5 according to different 
secretion of growth hormone (GH) in healthy male and female adult individuals [23]. However, the 
differences between our results and those of Kuyper et al. [21] and Velicković-Radovanović et al. 
[22] may well be due to the differences in the study protocol: sampling time points, children vs 
adults, liver vs kidney transplantation. It must also be considered that liver dysfunction often leads 
to endocrine perturbations through the abolition of the balanced crosstalk between the endocrine 
system and the hepatic microenvironment. Indeed, some studies have shown anomalies in the GH 
levels, possibly due to GH resistance, before liver transplantation, whereas the patients achieved an 
almost normal GH range only after a week from the liver transplantation [24-27]. Therefore, we 
could speculate that at a very early stage after liver transplantation, GH hormonal perturbation 
might affect the CYP3A5 enzyme expression in the donor liver, changing the physiological status 
of CYP3A5 enzyme induction. This alterations may have induced a higher CYP3A5 enzyme 
expression in male than in female liver grafts in our paediatric transplant population. However, 
according to our linear general model analysis, donor gender does not seem to influence tacrolimus 
disposition as much as donor CYP3A5 genotype and recipient age. 
The effect of age on tacrolimus disposition observed in our study are in agreement with previous 
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studies on paediatric renal and liver transplant recipients, with pre-pubertal children needing 2 to 3 
times higher doses than adults [28, 29]. Indeed, when we compared the tacrolimus 
concentration/weight-adjusted dose ratios in children who were younger or older than 6 years, we 
found a faster tacrolimus disposition in the younger group (Figure 2). 
When recipient and donor tacrolimus metabolism (whole body metabolism) were considered, 
CYP3A4/5 combined genotypes were strongly related to tacrolimus disposition on the first day after 
liver transplantation, but only to tacrolimus trough blood concentration (Figure 3). Rapid 
CYP3A4/5 metabolizers exhibited approximately 50% lower tacrolimus trough blood 
concentrations than did intermediate or extensive metabolizers on the first day after liver 
transplantation, while most of the rapid metabolizers were below the therapeutic range (Figure 3). 
These data are in agreement with those reported in paediatric heart transplant recipients, where slow 
CYP3A4/5 metabolizers required almost 20% less tacrolimus than did extensive metabolizers and 
approximately 50% less than rapid metabolizers [11].  
This discrepancy between tacrolimus blood trough concentration and tacrolimus 
concentration/weight-adjusted dose ratio in the tacrolimus whole body metabolism lead us to 
analyze the CYP3A4/5 genotypes in recipients (extrahepatic metabolism) and donors (hepatic 
metabolism) separately. A significant contribution in tacrolimus disposition attributable to the 
donor liver was observed. Conversely, recipient metabolism did not provide any significant 
contribution, thus confirming the crucial role that hepatic metabolism plays in tacrolimus 
disposition at a very early stage after liver transplantation [7, 30]. Nevertheless, CYP-dependent 
metabolism in children exceeds adult CYP activity, decreasing to adult levels around puberty. 
Therefore, our finding that children under 6 need higher doses of tacrolimus than adults, might be 
influenced by extrahepatic metabolism and not by hepatic metabolism, as also reported by Uesugi et 
al. [31]. This may been explained by the quick recovery of CYP3A enzyme activity in the liver 
graft after transplantation [32] and by different maturation changes in ontogeny of CYP3A5 activity 
between children and adults [33-35], together with the unique pathophysiological condition 
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occurring in patients undergoing a liver transplantation, which may also play an important role [36]. 
Lastly, the CYP3A4 genotype and CYP3A5 genotype contribution to tacrolimus hepatic metabolism 
on the first day after liver transplantation were investigated separately. The importance of the 
CYP3A5 genotype in tacrolimus disposition was confirmed, as most CYP3A5*1/*1 and *1/*3 
paediatric patients had tacrolimus concentrations under the therapeutic range, even at this very early 
stage after liver transplantation (Figure 4A and B), while the CYP3A4 genotype played only a minor 
role. Our results partially contrast with those of Guy-Viterbo et al. who reported that the presence of 
the CYP3A4*22 genotype in the liver donor decreased tacrolimus clearance by 29% [20]. This 
incongruity on the CYP3A4 genotype role in tacrolimus disposition may be due to differences 
between the study protocols. Our study investigated the tacrolimus trough blood concentration and 
concentration/weight-adjusted dose ratio by just one point blood sampling at a very early stage after 
liver transplantation, whereas Guy-Viterbo et al. [20] studied the CYP3A4 genotype contribution by 
blood sampling at several points up to 90 days after liver transplantation. Therefore, in our opinion, 
a phenomenon such as phenoconversion [37] or difference in CYP3A5 and CYP3A4 activity 
recovery after liver transplantation, may change the relative importance  of CYP3A5 and CYP3A4 
enzymes for tacrolimus disposition, the latter becoming more relevant over time. Consequently, it 
may be assumed that the tacrolimus metabolism over time might be related to liver function 
recovery rather than to the CYP3A5 enzyme activity [32]. 
In conclusion, our study shows that the initial disposition of tacrolimus in paediatric liver transplant 
patients is influenced by the liver donor CYP3A5 genotype, thus indicating that not only does the 
CYP3A5 enzyme play a major role over the CYP3A4 enzyme in the tacrolimus metabolism at this 
very early stage, but also that other physiological factors, mainly the recipient age, may also play a 
role. This finding is in agreement with data reported in paediatric heart transplant recipients, where 
age and CYP3A5 genotype were independently associated with the tacrolimus concentration/dose 
ratio [10]. 
We acknowledge that the comparatively small size of our paediatric population is a limiting factor 
20	
	
and that further research is required in support of these preliminary findings. However, this study 
suggests that, in paediatric patients under 6 years of age who receive a graft from a male extensive 
metabolizer, at least doubling the initial tacrolimus doses, when they are not yet TDM guided, may 
enhance the efficacy of immunosuppression.  
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Figure Legends 
Figure 1. (A) Tacrolimus trough concentration (C0) on the first day after liver transplantation in the 
whole paediatric population. The grey zone denotes the target therapeutic range in the first days 
after liver paediatric transplantation. (B) Tacrolimus concentration/weight-adjusted dose ratio on 
the first day after liver transplantation in the whole paediatric population. The horizontal line in the 
middle indicates the median; the top and the bottom lines mark the 75th and 25th percentiles, 
respectively. 
Figure 2. Tacrolimus concentration/weight-adjusted dose ratio on the first day after liver 
transplantation in paediatric patients who were younger and older than 6 years old. The horizontal 
line in the middle indicates the median; the top and the bottom lines mark the 75th and 25th 
percentiles, respectively. P < 0.05 statistically significant.  
Figure 3. Tacrolimus trough concentration (C0) on the first day after liver transplantation in 
paediatric patients according to the CYP3A4/5 combined-genotype approach on whole body 
metabolism. The grey zone denotes the therapeutic range in the first days after liver paediatric 
transplantation. The horizontal line in the middle indicates the median; the top and the bottom lines 
mark the 75th and 25th percentiles, respectively. RM: Rapid Metabolizer; EM: Extensive 
Metabolizer; IM: Intermediate Metabolizer. P < 0.05 Statistical significant.  
Figure 4. (A) Tacrolimus trough concentration (C0) on the first day after liver transplantation in 
paediatric patients according to liver CYP3A5 genotype. The grey zone denotes the therapeutic 
range in the first days after liver paediatric transplantation. (B) Tacrolimus concentration/weight-
adjusted dose ratio on the first day after liver transplantation in paediatric patients according to liver 
CYP3A5 genotype. The horizontal line in the middle indicates the median; the top and the bottom 
lines mark the 75th and 25th percentiles, respectively. P < 0.05 Statistically significant.  
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Table 1 Recipient and donor demographics	
 
 
 
 
 
 N % 
Patients 67 100 
Recipient gender (male/female) 33/34 49/51 
Donor gender      (male/female) 41/26 61/39 
Recipient age at transplantation (years, mean ± SD) 4.5 ± 5.2  
Donor age                                   (years, mean ± SD) 14 ± 12  
Weight at transplantation (kg, mean ± SD) 18.1 ± 15.7  
GRWR (median, IQR) 3.4 IQR 2.2  
Ethnicity: 
Caucasian 
Unknown 
52 
15 
78 
22 
Indication for liver transplantation: 
            Biliary atresia 
Primary liver tumour 
Primary sclerosing cholangitis 
Metabolic disease 
Vascular malformation 
Alagille syndrome 
Miscellaneous 
33 
14 
6 
4 
3 
2 
5 
49 
21 
9 
6 
5 
3 
7 
Additional therapy: 
Basiliximab  
Steroids 
52 
41 
78 
61 
Patients taking drugs potentially interfering with 
CYP3A (fluconazole and/or steroids) 50 75 
 
GRWR: 	Graft-Recipient Weight Ratio; IQR: Interquartile Range; CYP: Cytochrome P450 
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Table 2A CYP3A4/5 recipient and donor genotype profiles 
CYP3A4/5 Rapid metabolizers 
Number 17 5 1 1 
CYP3A4 recipient *1/*1 *1/*1 *1/*1 *1/*1 
CYP3A5 recipient *3/*3 *1/*3 *1/*1 *3/*3 
CYP3A4 donor *1/*1 *1/*1 *1/*1 *1/*1 
CYP3A5 donor *1/*3 *3/*3 *3/*3 *1/*1 
 
 
Table 2B CYP3A4/5 recipient and donor genotype profiles 
CYP3A4/5 Extensive metabolizers 
Number 24 3 2 2 1 
CYP3A4 recipient *1/*1 *1/*22 *1/*1 *1/*1 *1/*22 
CYP3A5 recipient *3/*3 *3/*3 *1/*3 *3/*3 *1/*3 
CYP3A4 donor *1/*1 *1/*1 *1/*22 *1/*22 *1/*1 
CYP3A5 donor *3/*3 *1/*3 *3/*3 *1/*3 *3/*3 
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Table 2C CYP3A4/5 recipient and donor genotype profiles 
CYP3A4/5 Intermediate metabolizers 
Number 6 2 1 1 1 
CYP3A4 recipient *1/*1 *22/*22 *1/*22 *1/*22 *1/*1 
CYP3A5 recipient *3/*3 *3/*3 *3/*3 *3/*3 *3/*3 
CYP3A4 donor *1/*22 *1/*1 *1/*1 *1/*22 *22/*22 
CYP3A5 donor *3/*3 *3/*3 *3/*3 *3/*3 *3/*3 
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